April 22nd 2024
Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Use of Systemic Treatment in Plaque Psoriasis
Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.
Patient Case #2: 23-Year-Old Female With Plaque Psoriasis
Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.
Importance of Long-Term Safety Data in Plaque Psoriasis Treatment
Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.
Systemic Treatment Options in Plaque Psoriasis
Laura Bush, DMSc, PA-C, provides an overview of systemic treatment options for patients with plaque psoriasis, highlighting the follow-up process once treatment has been implemented.
Leah Howard, JD: Advocacy in Chronic Skin Conditions
August 18th 2023Following this week's Science of Skin media roundtable hosted by AbbVie, panelist and National Psoriasis Foundations President and CEO Leah Howard, JD, discusses the importance of advocacy and mental health in chronic skin conditions.
CASE 1 Presentation: 60-year-old African American Woman With GPP
August 17th 2023Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.
Escalating Treatment From Topical to Systemic in Plaque Psoriasis
Jennifer Conner, MPAS, PA-C, and Lakshi Aldredge, MSN, ANP-BC, comment on approaches to escalating treatment of plaque psoriasis from topical therapy to systemic therapy and initiating that conversation with the patient.
Patient Case #1: 50-Year-Old Female With Plaque Psoriasis
Experts in dermatology review a case of a patient with plaque psoriasis concentrated on her hands and discuss taking the patient’s preferences into consideration when selecting treatment.